Esophageal squamous cell carcinoma

This study tests whether adding lenvatinib to pembrolizumab and chemotherapy helps people with metastatic esophageal cancer live longer. About 864 participants receive either the new three-drug combo or standard care. The goal is to improve overall survival, but this is not a cur…

This early-stage trial tested an oral drug called TNO155, alone or with another drug (nazartinib), in 227 adults with advanced solid tumors like lung cancer, melanoma, and head/neck cancer. The main goal was to check safety and find the right dose. The study was terminated early,…

This early-phase study tested a new drug called BGB-24714, which is designed to help cancer cells die. It was given alone or with chemotherapy to 157 adults with advanced solid tumors that had spread or could not be removed. The main goal was to find a safe dose and see how well …

This early-stage trial tested a new drug, QEQ278, in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

This early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated…

This early-stage study tested a new drug (JS004) combined with another immunotherapy (Toripalimab) in 31 people with advanced solid tumors like liver, esophageal, stomach, cervical, or colorectal cancer. The goal was to check safety and see if the combination could help control t…

This early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…

This early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was termina…

This phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so t…

This study tests two AI models that analyze endoscopy and CT images to diagnose esophageal cancer and predict how deep the tumor has grown. The goal is to help doctors decide if a patient can be treated with a less invasive endoscopic procedure or needs more aggressive therapy. T…

This small pilot study tested whether applying acupressure to the ear could help improve appetite and prevent weight loss in people with advanced stomach, esophagus, or pancreatic cancer. The approach uses small adhesive pellets placed on specific ear spots to stimulate the nervo…

This study is measuring how often a specific genetic marker (HLA-A*02:01) and a cancer-related protein (NY-ESO-1) appear in Taiwanese patients with solid tumors like head and neck, liver, lung, breast, and esophageal cancers. By understanding these frequencies, researchers hope t…

This study aimed to find out if patients with metastatic esophageal cancer who were not getting worse after 6 weeks of chemotherapy should continue treatment or stop. It included 15 adults whose cancer had spread and was no longer responding to initial chemo. The study was termin…